Earnings summaries and quarterly performance for SERA PROGNOSTICS.
Executive leadership at SERA PROGNOSTICS.
Zhenya Lindgardt
Detailed
President and Chief Executive Officer
CEO
AA
Austin Aerts
Detailed
Chief Financial Officer
BJ
Benjamin Jackson
Detailed
General Counsel
JB
John Boniface
Detailed
Chief Scientific Officer
LA
Lee Anderson
Detailed
Chief Commercial Officer
PK
Paul Kearney
Detailed
Chief Data Officer
RH
Robert Harrison
Detailed
Chief Information Officer
Board of directors at SERA PROGNOSTICS.
Research analysts who have asked questions during SERA PROGNOSTICS earnings calls.
MB
Margarate Boeye
Raymond James
2 questions for SERA
Also covers: ADPT, AWH
DB
Dan Brennan
UBS
1 question for SERA
Also covers: A, ADPT, DHR +10 more
Daniel Brennan
TD Cowen
1 question for SERA
Also covers: A, ADPT, AVTR +24 more
MB
Maggie Boeye
William Blair
1 question for SERA
Also covers: QDEL, VCYT, XGN
WR
William Ruby
TD Cowen
1 question for SERA
Also covers: BDSX, PACB, PSNL +1 more
Recent press releases and 8-K filings for SERA.
Sera Prognostics, Inc. Posts Investor Presentation Highlighting PreTRM® Test and Commercialization Strategy
SERA
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Sera Prognostics, Inc. published an investor presentation on January 8, 2026, detailing its strategy to redefine pregnancy care and reduce preterm birth burden with its PreTRM® test.
- The company reported $102.4 million in cash, cash equivalents, and marketable securities as of September 30, 2025, providing a cash runway through 2028.
- The recently published PRIME study demonstrated that the PreTRM® test, combined with targeted interventions, resulted in 20% fewer babies admitted to the NICU, 56% fewer babies born before 32 weeks, and a 20% reduction in neonatal morbidity.
- Sera Prognostics is entering the commercialization stage for the PreTRM® test, focusing on targeted geographies and engaging Medicaid plans and commercial payers, with pilot programs already launched.
- The company aims to address the $25.2 billion economic cost of preterm birth in the US, with health economic data suggesting $4,234 savings per person screened for an example small insurance plan.
Jan 8, 2026, 10:20 PM
Sera Prognostics Announces Positive PRIME Study Results for PreTRM® Test
SERA
New Projects/Investments
- Sera Prognostics, Inc. announced the publication of the results of the PRIME study in the Pregnancy Journal, demonstrating that its PreTRM® Blood Test significantly reduces earliest preterm births and newborn complications.
- Key findings from the study include 56% fewer babies born before 32 weeks and 32% fewer before 35 weeks, along with a 20% reduction in NICU admissions and neonatal morbidity.
- The PreTRM Test is a personalized, non-invasive blood test that predicts the risk of spontaneous preterm birth in asymptomatic women carrying a single baby.
- The company's President and CEO, Zhenya Lindgardt, and other key personnel will discuss the full results during a Jefferies fireside chat on January 9, 2026, at 8:30 am ET.
Jan 7, 2026, 2:12 PM
Sera Prognostics: PRIME Study Demonstrates Significant Improvements with PreTRM Test
SERA
New Projects/Investments
Revenue Acceleration/Inflection
- The PRIME Study, published in PREGNANCY, found that Sera Prognostics' PreTRM Test combined with targeted interventions significantly reduced preterm births (e.g., 56% fewer babies born before 32 weeks) and improved neonatal outcomes, including a 20% reduction in NICU admissions.
- The PreTRM Test is a personalized, non-invasive blood test that predicts the risk of spontaneous preterm birth in asymptomatic women carrying a single baby, enabling early identification and preventive care.
- These findings reinforce previous results and are expected to transform maternal and neonatal health outcomes, aiming to establish a new commercial and clinical standard.
- Company executives will discuss the full PRIME study results during a Jefferies fireside chat on January 9, 2026.
Jan 7, 2026, 1:30 PM
Sera Prognostics Reports Q3 2025 Results and Commercialization Progress
SERA
Earnings
New Projects/Investments
Revenue Acceleration/Inflection
- Sera Prognostics reported net revenue of $16,000 and a net loss of $7.8 million for Q3 2025, maintaining a cash position of approximately $102.4 million as of September 30, 2025.
- The company's first Medicaid pilot in Nevada is actively enrolling patients, for which it received a $100,000 prepayment.
- Sera is expanding its commercial efforts, engaging with 10 payers across 13 states and completing the hiring of sales representatives across all six initial target states to drive PreTRM test adoption.
- The full results of the pivotal PRIME study are expected to be published in a peer-reviewed journal by the end of 2025, which is crucial for formal payer policy review and accelerating commercialization.
- For 2026, the company anticipates overall expenses to remain relatively flat, with a significant increase in sales and marketing expenses as capital is reallocated towards commercialization.
Nov 13, 2025, 10:00 PM
Sera Prognostics Reports Third Quarter 2025 Financial Results
SERA
Earnings
New Projects/Investments
Management Change
- Sera Prognostics Inc. reported revenue of $16,000 and a net loss of $7.8 million for the third quarter of 2025.
- Total operating expenses for the quarter were $9.0 million.
- As of September 30, 2025, the company had approximately $102.4 million in cash, cash equivalents, and available-for-sale securities, which is expected to fund the company through 2028.
- The company made meaningful progress on payer initiatives, including an inaugural Medicaid pilot in Nevada, and is on track to publish full PRIME study results this year.
- Key leadership appointments include Dr. Tiffany Inglis as Chief Medical Officer and Marisol Urbano as Head of Commercial Operations.
Nov 13, 2025, 9:09 PM
Sera Prognostics Reports Third Quarter 2025 Financial Results
SERA
Earnings
New Projects/Investments
Management Change
- Sera Prognostics reported third quarter 2025 revenue of $16,000, a decrease from $29,000 in Q3 2024, while its net loss improved slightly to $7.8 million from $7.9 million in the same period last year.
- As of September 30, 2025, the company held approximately $102.4 million in cash, cash equivalents, and available-for-sale securities, which is anticipated to fund operations through 2028.
- The company made progress on payer initiatives, including launching a Medicaid pilot in Nevada, and strengthened its leadership with the appointment of Dr. Tiffany Inglis as Chief Medical Officer and Marisol Urbano as Head of Commercial Operations.
Nov 13, 2025, 9:05 PM
Sera Prognostics Discusses Preterm Birth Diagnostic Test Results and Commercial Strategy
SERA
New Projects/Investments
Revenue Acceleration/Inflection
Guidance Update
- Sera Prognostics' CEO, Zhenya Lindgardt, emphasized the critical issue of preterm birth in the U.S., impacting one in ten babies and incurring an annual cost of approximately $25 billion to the healthcare system.
- The company's pivotal PRIME study, when combined with previous AVERT trial data, demonstrated a 22% reduction in severe neonatal outcomes and length of stay, including a notable 20%-22% reduction in NICU admissions.
- Sera's diagnostic blood test, administered between weeks 18 and 20 of pregnancy, shows strong economic value, with a "number needed to screen" of 3-4 women to save one NICU day and an estimated $2,200 in savings per NICU day saved.
- Sera Prognostics currently has a cash runway through 2028, not including future revenue, which the company believes is sufficient to achieve significant scale and potentially break-even.
Mar 5, 2025, 2:50 PM
Sera Prognostics Discusses Preterm Birth Diagnostic Test Results and Commercial Strategy
SERA
New Projects/Investments
Revenue Acceleration/Inflection
- Sera Prognostics' pivotal PRIME study demonstrated a 25% reduction in neonatal morbidity and mortality (NMI) and an 18% reduction in neonatal length of stay for its preterm birth diagnostic test. When combined with the Overt study, the test consistently showed a 22% reduction in severe outcomes for babies and length of stay.
- The test also achieved a 20%-22% reduction in NICU admission. Economically, screening three to four women can save one NICU day, translating to approximately $3,000 in savings per day, while payer Elevance estimated $1,600 savings per member tested.
- Sera's strategy for guideline adoption includes publishing extensive data from the PRIME study, collaborating on implementation protocols and reimbursement, and driving adoption in major institutions to influence professional societies.
- The company projects a cash runway through 2028, excluding revenue proceeds, with expectations for it to extend further as revenue ramps up.
Mar 5, 2025, 2:50 PM
Quarterly earnings call transcripts for SERA PROGNOSTICS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more